Patent US4308251A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4308251A Expired / Lapsed US ⏱️ 0.0 years remaining

Controlled release formulations of orally-active medicaments

Assignee: Knoll Pharmaceutical Co
•
Filing: 1980-10-17
•
Granted: 1981-12-29
•
Expires: 2000-10-17
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract An improved tablet formulation is provided comprising an effective amount of an active therapeutic agent, especially an acidic therapeutic agent such as aspirin, a release-controlling agent, and an erosion-promoting agent in relative amounts to provide a criticality factor of less than 450, and in proportions of release-controlling and erosion-promoting agent, respectively, between 0.8-1.6 and 1.0-7.5 weight percent per tablet. The tablets of this invention exhibit zero order release in vitro and closely approximate zero order absorption in vivo. The aspirin tablets of the invention produce minimal epigastric distress and can be administered twice-a-day to provide the desired therapeutic effect. The preferred release-controlling agent is cellulose acetate phthalate and the preferred erosion-promoting agent is corn starch.

Inventors

  • 👤 James M. Dunn
  • 👤 John F. Lampard

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-31 08:37
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/20; A61K9/2004; A61K9/2022; A61K9/205; A61K9/2054; A61K9/2059

Claims Analysis

Total Claims: 26
Claim 1
Independent Claim 202 words
A compressed, controlled-release tablet suitable for oral administration, said tablet consisting essentially of an effective amount of an orally-active therapeutic agent selected from aspirin and a nonsteroidal arylalkanoic anti-inflammatory agent, a release-controlling agent, and an erosion-promoting agent, in proportions which provide a criticality factor between 20 and 450, calculated according to the formula: CA/(1/CS)=CF wherein: CA is the milligram per tablet content of therapeutic agent divided by the milligram per tablet content of release-controlling agent, CS is the milligram per tablet content of erosion-promoting agent divided by the milligram per tablet content of release-controlling agent, and CF is the criticality factor, said proportions including 0.8 to 1.6 weight percent per tablet of said release-controlling agent and 1.0 to 7.5 weight percent per tablet of said erosion-promoting agent, wherein the release-controlling agent is selected from the group consisting of cellulose acetate phthalate, cellulose acetate derivatives, shellac, zein, acrylic resins, ethylcellulose, hydroxypropylmethylcellulose phthalate, sandarac, and modified shellac; and wherein the erosion-promoting agent is selected from the group consisting of corn starch, rice starch, potato starch and other vegetable starches, modified starch, starch derivatives, cellulose, cellulose derivatives, modified cellulose, modified cellulose derivatives, alginic acid, alginates, bentonite, veagum, cross-linked polyvinyl pyrrolidone, ion exchange resins, and gums.
Claim 2
Dependent Claim 202 words
A compressed, controlled-release tablet suitable for oral administration, said tablet consisting essentially of an effective amount of an orally-active therapeutic agent selected from aspirin and a nonsteroidal arylalkanoic anti-inflammatory agent, a release-controlling agent, and an erosion-promoting agent, in proportions which provide a criticality factor between 20 and 450, calculated according to the formula: CA/(1/CS)=CF wherein: CA is the milligram per tablet content of therapeutic agent divided by the milligram per tablet content of release-controlling agent, CS is the milligram per tablet content of erosion-promoting agent divided by the milligram per tablet content of release-controlling agent, and CF is the criticality factor, said proportions including 0.8 to 1.6 weight percent per tablet of said release-controlling agent and 1.0 to 7.5 weight percent per tablet of said erosion-promoting agent, wherein the release-controlling agent is selected from the group consisting of cellulose acetate phthalate, cellulose acetate derivatives, shellac, zein, acrylic resins, ethylcellulose, hydroxypropylmethylcellulose phthalate, sandarac, and modified shellac; and wherein the erosion-promoting agent is selected from the group consisting of corn starch, rice starch, potato starch and other vegetable starches, modified starch, starch derivatives, cellulose, cellulose derivatives, modified cellulose, modified cellulose derivatives, alginic acid, alginates, bentonite, veagum, cross-linked polyvinyl pyrrolidone, ion exchange resins, and gums.
Claim 3
Dependent Claim 11 words
The tablet of claim 1 wherein the criticality factor is 80-330.
Claim 4
Dependent Claim 11 words
The tablet of claim 1 wherein the criticality factor is 210-330.
Claim 5
Dependent Claim 13 words
The tablet of claim 1 wherein said release-controlling agent is cellulose acetate phthalate.
Claim 6
Dependent Claim 12 words
The tablet of claim 1 wherein said erosion-promoting agent is corn starch.
Claim 7
Dependent Claim 20 words
The tablet of claim 2 wherein said release-controlling agent is cellulose acetate phthalate and said erosion-promoting agent is corn starch.
Claim 8
Dependent Claim 11 words
The tablet of claim 1 wherein said therapeutic agent is aspirin.
Claim 9
Dependent Claim 11 words
The tablet of claim 2 wherein said therapeutic agent is aspirin.
Claim 10
Dependent Claim 11 words
The tablet of claim 3 wherein said therapeutic agent is aspirin.
Claim 11
Dependent Claim 11 words
The tablet of claim 4 wherein said therapeutic agent is aspirin.
Claim 12
Dependent Claim 11 words
The tablet of claim 5 wherein said therapeutic agent is aspirin.
Claim 13
Dependent Claim 11 words
The tablet of claim 6 wherein said therapeutic agent is aspirin.
Claim 14
Dependent Claim 17 words
The tablet of claim 1 wherein said therapeutic agent is 650 to about 800 mg of aspirin.
Claim 15
Dependent Claim 17 words
The tablet of claim 4 wherein said therapeutic agent is 650 to about 800 mg of aspirin.
Claim 16
Dependent Claim 17 words
The tablet of claim 5 wherein said therapeutic agent is 650 to about 800 mg of aspirin.
Claim 17
Dependent Claim 17 words
The tablet of claim 6 wherein said therapeutic agent is 650 to about 800 mg of aspirin.
Claim 18
Dependent Claim 15 words
The tablet of claim 1 wherein said therapeutic agent is a nonsteroidal arylalkanoic anti-inflammatory agent.
Claim 19
Dependent Claim 14 words
The tablet of claim 2 wherein said therapeutic agent is 400-600 mg of ibuprofen.
Claim 20
Dependent Claim 14 words
The tablet of claim 1 wherein said therapeutic agent is 100-300 mg of flurbiprofen.
Claim 21
Dependent Claim 14 words
The tablet of claim 17, wherein said release control agent is cellulose acetate phthalate.
Claim 22
Dependent Claim 14 words
The tablet of claim 18, wherein said release control agent is cellulose acetate phthalate.
Claim 23
Dependent Claim 14 words
The tablet of claim 19, wherein said release control agent is cellulose acetate phthalate.
Claim 24
Dependent Claim 20 words
The tablet of claim 17, wherein said release control agent is cellulose acetate phthalate and said erosion-promoting agent is starch.
Claim 25
Dependent Claim 21 words
The tablet of claim 18, wherein said release control agent is cellulose acetate phthalate and said erosion-promoting agent is corn starch.
Claim 26
Dependent Claim 21 words
The tablet of claim 19, wherein said release control agent is cellulose acetate phthalate and said erosion-promoting agent is corn starch.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1984-12-28 1985-06-29 1985-12-29 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1988-12-28 1989-06-29 1989-12-29 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1992-12-28 1993-06-29 1993-12-29 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag